Identify and Validate the Transcriptomic, Functional Network, and Predictive Validity of FBXL19-AS1 in Hepatocellular Carcinoma

Abstract

Hepatocellular carcinoma (HCC) is one of the most common neoplastic diseases worldwide. Available biomarkers are not sensitive enough for the diagnosis of HCC, hence seeking new biomarkers of HCC is urgent and challenging. The purpose of this study was to investigate the role of F-box and leucine-rich repeat protein 19-antisense RNA 1 (FBXL19-AS1) through a functional network and inquire into its diagnostic and prognostic value in HCC. A comprehensive strategy of genomic data mining, bioinformatics and experimental validation was used to evaluate the clinical value of FBXL19-AS1 in the diagnosis and prognosis of HCC and to identify the pathways in which FBXL19-AS1 might be involved. FBXL19-AS1 was up-regulated in HCC tissues, and its high expression was associated with TNM stage and poor prognosis of HCC patients. The combination of FBXL19-AS1 and alpha-fetoprotein (AFP) in plasma could prominently improve the diagnostic validity for HCC. FBXL19-AS1 might stabilize FBXL19 to reduce the amount of macrophage M1, and then promote the occurrence and development of HCC. Meanwhile, FBXL19-AS1 might participate in regulating HCC related pathways through FBXL19-AS1-miRNA-mRNA network. Our findings indicated that FBXL19-AS1 not only serves as a potential biomarker for HCC diagnosis and prognosis, but also might be functionally carcinogenic.

FLVCR1-AS1 and FBXL19-AS1: Two Putative lncRNA Candidates in Multiple Human Cancers

“…Furthermore, another study revealed a positive correlation between FBXL19-AS1 TNM stage and poor prognosis of HCC patients, where FBXL19-AS1 acts as a regulation agent, controlling HCC-associated pathways, including cell cycle, microRNAs in cancer, viral carcinogenesis via ceRNA network [ 43 ]. Consequently, this lncRNA may be considered a diagnostic and prognostic biomarker [ 44 ]. Furthermore, a study demonstrated that lncRNA FBXL19-AS1 has a diagnostic biomarker potential and is considered an appropriate candidate as a prognosis biomarker in HCC [ 45 ].…”

“…Many studies have revealed that FBXL19-AS1 can regulate the expression of specific miRNAs that play an oncogenic role in various cancers. FBXL19-AS1 causes cancers by acting in different signaling pathways ( Figure 6 ; Table 4 ) [ 42 , 43 , 44 , 45 , 46 , 47 , 48 , 49 , 50 , 51 , 52 , 53 , 54 , 55 , 56 , 57 , 58 , 59 , 60 ].…”

“…The oncogenic role of lncRNA has been described in several cancers, such as hepatocellular cancer and cholangiocarcinoma [ 42 , 43 , 44 , 45 ], gastric cancer [ 46 , 47 ], colorectal cancer [ 48 ], glioma [ 49 ], lung cancer [ 50 , 51 , 52 ], cervical cancer (CC) [ 53 , 54 ], breast cancer [ 55 , 56 , 57 ], osteosarcoma [ 58 ], nasopharyngeal carcinoma (NPC) [ 59 ], and acute myeloid leukemia (AML) [ 60 ].…”

Emerging Roles and Mechanisms of lncRNA FOXD3-AS1 in Human Diseases

“…Liver cancer is considered the sixth most frequent type of cancer, while hepatocellular carcinoma (HCC) is the most common type of liver cancer, consisting of 75-85% of all cases according to GLOBOCAN 2018 data (87,(99)(100)(101). Currently, serum AFP is the most widely used biomarker for HCC screening, despite its low sensitivity and a high false-negative rate for early HCC diagnosis.…”